Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.
Non-Small Cell Lung Cancer
ALK‐ vs EGFR‐Positive NSCLC: CT Imaging and Clinical Characteristics
NSCLC characterized by ALK or EGFR molecular alterations produced different findings on CT scan images.
Genomic Profiling Using Guardant 360 Cell-Free DNA-Based Assay vs Tumor-Based Genotyping Assays in Advanced NSCLC
The Guardant360 assay is as effective as traditional tumor-based genotyping assays in identifying genomic alterations, according to researchers.
Overall Survival in Patients With Stage IV ALK-Positive Non-Small Cell Lung Cancer Treated With Crizotinib
Researchers found that survival was associated with the number of metastatic sites, but not affected by brain metastasis.
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
Better collaboration between community and academic cancer centers could benefit patients.
Checkpoint Inhibitor Pneumonitis in NSCLC
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
Further Development of Hsp90 Inhibitor in NSCLC Remains Uncertain
This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug’s codevelopers.
Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future
Scientific models project a continued decrease in lung cancer mortality.
Management of Hyperprogressive Disease in Nivolumab-Treated Lung Cancer
Management strategies were identified for lung cancer patients who experienced hyperprogressive disease during treatment with nivolumab.
First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Next post in ESMO 2018
